Helius Medical (HSDT) Technologies announced positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis. PoNSTEP Results: There were statistically significant findings in DGI during Phase 1 and Phase 2 among the 38 subjects who completed the treatment protocol for a total mean improvement of 5.00 at week 14. In Phase 2, average therapy adherence 71% and gait improvement was linearly associated with adherence, while, in Phase 1 adherence, was 89.5% and, consequently, not associated with improvement. In addition to mean 2.5 points improvement in DGI achieved in Phase 1, Phase 2, participants with greater than or equal to85% adherence improved mean 3.7 points; those with less than85% adherence improved mean 2.0 points, and the difference was statistically significant. 28 of 41 participants who completed the 14-wk therapy were reassessed at 6-months and only 1 of 28 showed greater than or equal to 30% decline in DGI. Mean decline in DGI was -4.1 with the 95% CI’s lower bound showing statistically reliable evidence that the true mean decline was no more than -9.4%.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.